Latent membrane protein 1, Latent membrane protein 2, and Epstein–Barr nuclear antigen 1 peptide-major histocompatibility complex (LMP1, LMP2, and EBNA1 peptide-MHC complex)

Peptide-MHC complexes involving EBV-encoded latent proteins—LMP1, LMP2, and EBNA1—present immunodominant viral epitopes on HLA class I or II molecules, enabling recognition by cytotoxic T lymphocytes (CTLs) and making them key immunological targets for therapies in EBV-associated diseases. These targets form the molecular basis for T cell-based and antibody-based immunotherapies, and their immunogenicity and disease selectivity make them appealing in cancers such as nasopharyngeal carcinoma and B cell lymphomas. However, the “LMP1, LMP2, and EBNA1 peptide-MHC complex” entry is an aggregate of multiple, functionally distinct complexes. For precise therapeutic or diagnostic applications, the peptide-MHC complexes should be specified for each antigen individually.

Other names

EBV latent antigen peptide-MHC complexEBV-derived peptide-MHC complexesEBV T cell epitope-MHC complex

Targeting by monoclonal antibodies for antibody-dependent cellular cytotoxicity Recognition and lysis by cytotoxic T lymphocytes, leading to destruction of EBV-infected or malignant cells